Cargando…

Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination

BACKGROUND: The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been demonstrated to induce secretory antibodies in the oral and nasal cavities in additi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishizaka, Aya, Koga, Michiko, Mizutani, Taketoshi, Uraki, Ryuta, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Yamamoto, Shinya, Imai, Masaki, Tsutsumi, Takeya, Suzuki, Yutaka, Kawaoka, Yoshihiro, Yotsuyanagi, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339591/
https://www.ncbi.nlm.nih.gov/pubmed/37443091
http://dx.doi.org/10.1186/s12985-023-02113-z
_version_ 1785071879820673024
author Ishizaka, Aya
Koga, Michiko
Mizutani, Taketoshi
Uraki, Ryuta
Yamayoshi, Seiya
Iwatsuki-Horimoto, Kiyoko
Yamamoto, Shinya
Imai, Masaki
Tsutsumi, Takeya
Suzuki, Yutaka
Kawaoka, Yoshihiro
Yotsuyanagi, Hiroshi
author_facet Ishizaka, Aya
Koga, Michiko
Mizutani, Taketoshi
Uraki, Ryuta
Yamayoshi, Seiya
Iwatsuki-Horimoto, Kiyoko
Yamamoto, Shinya
Imai, Masaki
Tsutsumi, Takeya
Suzuki, Yutaka
Kawaoka, Yoshihiro
Yotsuyanagi, Hiroshi
author_sort Ishizaka, Aya
collection PubMed
description BACKGROUND: The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been demonstrated to induce secretory antibodies in the oral and nasal cavities in addition to a systemic immune response. However, the mechanism of induced immune stimulation effect on mucosal immunity and commensal bacteria profile remains unclear. METHODS: Here, we longitudinally analysed the changing nasal microbiota and both systemic and nasal immune response upon SARS-CoV-2 mRNA vaccination, and evaluated how mRNA vaccination influenced nasal microbiota in 18 healthy participants who had received the third BNT162b. RESULTS: The nasal S-RBD IgG level correlated significantly with plasma IgG levels until 1 month and the levels were sustained for 3 months post-vaccination. In contrast, nasal S-RBD IgA induction peaked at 1 month, albeit slightly, and correlated only with plasma IgA, but the induction level decreased markedly at 3 months post-vaccination. 16 S rRNA sequencing of the nasal microbiota post-vaccination revealed not an overall change, but a decrease in certain opportunistic bacteria, mainly Fusobacterium. The decrease in these bacteria was more pronounced in those who exhibited nasal S-RBD IgA induction, and those with higher S-RBD IgA induction had lower relative amounts of potentially pathogenic bacteria such as Pseudomonas pre-vaccination. In addition, plasma and mucosal S-RBD IgG levels correlated with decreased commensal pathogens such as Finegoldia. CONCLUSIONS: These findings suggest that the third dose of SARS-CoV-2 mRNA vaccination induced S-RBD antibodies in the nasal mucosa and may have stimulated mucosal immunity against opportunistic bacterial pathogens. This effect, albeit probably secondary, may be considered one of the benefits of mRNA vaccination. Furthermore, our data suggest that a cooperative function of mucosal and systemic immunity in the reduction of bacteria and provides a better understanding of the symbiotic relationship between the host and bacteria in the nasal mucosa. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02113-z.
format Online
Article
Text
id pubmed-10339591
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103395912023-07-14 Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination Ishizaka, Aya Koga, Michiko Mizutani, Taketoshi Uraki, Ryuta Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Yamamoto, Shinya Imai, Masaki Tsutsumi, Takeya Suzuki, Yutaka Kawaoka, Yoshihiro Yotsuyanagi, Hiroshi Virol J Research BACKGROUND: The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been demonstrated to induce secretory antibodies in the oral and nasal cavities in addition to a systemic immune response. However, the mechanism of induced immune stimulation effect on mucosal immunity and commensal bacteria profile remains unclear. METHODS: Here, we longitudinally analysed the changing nasal microbiota and both systemic and nasal immune response upon SARS-CoV-2 mRNA vaccination, and evaluated how mRNA vaccination influenced nasal microbiota in 18 healthy participants who had received the third BNT162b. RESULTS: The nasal S-RBD IgG level correlated significantly with plasma IgG levels until 1 month and the levels were sustained for 3 months post-vaccination. In contrast, nasal S-RBD IgA induction peaked at 1 month, albeit slightly, and correlated only with plasma IgA, but the induction level decreased markedly at 3 months post-vaccination. 16 S rRNA sequencing of the nasal microbiota post-vaccination revealed not an overall change, but a decrease in certain opportunistic bacteria, mainly Fusobacterium. The decrease in these bacteria was more pronounced in those who exhibited nasal S-RBD IgA induction, and those with higher S-RBD IgA induction had lower relative amounts of potentially pathogenic bacteria such as Pseudomonas pre-vaccination. In addition, plasma and mucosal S-RBD IgG levels correlated with decreased commensal pathogens such as Finegoldia. CONCLUSIONS: These findings suggest that the third dose of SARS-CoV-2 mRNA vaccination induced S-RBD antibodies in the nasal mucosa and may have stimulated mucosal immunity against opportunistic bacterial pathogens. This effect, albeit probably secondary, may be considered one of the benefits of mRNA vaccination. Furthermore, our data suggest that a cooperative function of mucosal and systemic immunity in the reduction of bacteria and provides a better understanding of the symbiotic relationship between the host and bacteria in the nasal mucosa. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02113-z. BioMed Central 2023-07-13 /pmc/articles/PMC10339591/ /pubmed/37443091 http://dx.doi.org/10.1186/s12985-023-02113-z Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ishizaka, Aya
Koga, Michiko
Mizutani, Taketoshi
Uraki, Ryuta
Yamayoshi, Seiya
Iwatsuki-Horimoto, Kiyoko
Yamamoto, Shinya
Imai, Masaki
Tsutsumi, Takeya
Suzuki, Yutaka
Kawaoka, Yoshihiro
Yotsuyanagi, Hiroshi
Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
title Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
title_full Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
title_fullStr Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
title_full_unstemmed Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
title_short Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
title_sort antibody induction and immune response in nasal cavity by third dose of sars-cov-2 mrna vaccination
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339591/
https://www.ncbi.nlm.nih.gov/pubmed/37443091
http://dx.doi.org/10.1186/s12985-023-02113-z
work_keys_str_mv AT ishizakaaya antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT kogamichiko antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT mizutanitaketoshi antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT urakiryuta antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT yamayoshiseiya antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT iwatsukihorimotokiyoko antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT yamamotoshinya antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT imaimasaki antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT tsutsumitakeya antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT suzukiyutaka antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT kawaokayoshihiro antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination
AT yotsuyanagihiroshi antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination